Jane Street’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jane Street’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$270K	Sell	5,600 -600	-10%	-$26.6K	﹤0.01%	9463
2025 Q4	$256K	Buy	+6,200	New	+$249K	﹤0.01%	9193
2025 Q3	–	Sell	-28,000	Closed	-$775K	–	11324
2025 Q2	$775K	Buy	+28,000	New	+$713K	﹤0.01%	6083
2022 Q3	–	Sell	-56,000	Closed	-$542K	–	10089
2022 Q2	$542K	Buy	56,000 +31,000	+124%	+$289K	﹤0.01%	6598
2022 Q1	$249K	Sell	25,000 -6,300	-20%	-$66.7K	﹤0.01%	8690
2021 Q4	$368K	Buy	+31,300	New	+$385K	﹤0.01%	7800

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street's KNSA Position: Q1 2026 in Review

Jane Street sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 242,430 shares — an estimated $10.7M sold.

Jane Street first reported a position in KNSA in Q3 2020 and held it in 16 quarters. The position peaked at $17.9M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Jane Street reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 242,430 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $10.7M.
Jane Street first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 16 quarters.
Jane Street's Kiniksa Pharmaceuticals position peaked at $17.9M in Q3 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.